1M6MYTD1Y5YMAX
Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | December 2025 | |
|---|---|---|
| Revenue | 35.97K | - |
| Gross profit | -254.31K | - |
| Net profit | -718.14K | - |
| EBITDA | -735.66K | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €5.03M |
Number of shares | 239.18M |
52-week high/low | €0.0482 - €0.0148 |
| Dividends | No |
Beta | 0.82 |
P/E ratio | -3.21 |
PEG ratio | 0.09 |
P/B ratio | 4.27 |
P/S ratio | 21.30 |
Company profile
Firebrick Pharma Limited befasst sich mit der Entwicklung und Vermarktung von Nasensprays zur Behandlung von Erkältungskrankheiten unter dem Namen Nasodine in Australien. Das Unternehmen wurde im Jahr 2012 gegründet und hat seinen Sitz in Melbourne, Australien.
| Name | FIREBRICK PHARMA LTD Aktie |
| CEO | Peter Laurence Molloy |
| Headquarters | Melbourne,
vic USA |
| Website | |
| Industry | Food Products |
| IPO | 02/04/2021 |
| Employees | 6 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Australian Securities Exchange Ltd | FRE.AX |
Discover assets
Shareholders of FIREBRICK PHARMA LTD Aktie also invest in the following assets
